Next-generation therapies for adrenocortical carcinoma
Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …
[HTML][HTML] Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
A Rekowska, P Rola, M Wójcik-Superczyńska… - Current …, 2022 - mdpi.com
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the
leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung …
leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung …
[HTML][HTML] A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma
C Chang, X Sun, G Wang, H Yu, W Zhao, Y Ge… - Frontiers in …, 2021 - frontiersin.org
Objectives Anaplastic lymphoma kinase (ALK) rearrangement status examination has been
widely used in clinic for non-small cell lung cancer (NSCLC) patients in order to find patients …
widely used in clinic for non-small cell lung cancer (NSCLC) patients in order to find patients …
The big data paradox in clinical practice
P Msaouel - Cancer investigation, 2022 - Taylor & Francis
The big data paradox is a real-world phenomenon whereby as the number of patients
enrolled in a study increases, the probability that the confidence intervals from that study will …
enrolled in a study increases, the probability that the confidence intervals from that study will …
Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non–small-cell lung cancer in the netherlands
HB Wolff, EMP Steeghs, ZA Mfumbilwa… - JCO Precision …, 2022 - ascopubs.org
PURPOSE A large number of targeted treatment options for stage IV nonsquamous non–
small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is …
small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is …
[HTML][HTML] The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung …
J Gao, R Niu, Y Shi, X Shao, Z Jiang, X Ge, Y Wang… - EJNMMI research, 2023 - Springer
Background This study aims to construct radiomics models based on [18F] FDG PET/CT
using multiple machine learning methods to predict the EGFR mutation status of lung …
using multiple machine learning methods to predict the EGFR mutation status of lung …
Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors
Epidermal growth factor receptor (EGFR) is a validated drug target for cancer chemotherapy.
Mutations in EGFR are directly linked with the development of drug resistance and this has …
Mutations in EGFR are directly linked with the development of drug resistance and this has …
[HTML][HTML] Transfer learning–based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in …
Background To introduce a three-dimensional convolutional neural network (3D CNN)
leveraging transfer learning for fusing PET/CT images and clinical data to predict EGFR …
leveraging transfer learning for fusing PET/CT images and clinical data to predict EGFR …
[HTML][HTML] Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
Q Sun, Z Lu, Y Zhang, D Xue, H Xia, J She, F Li - Cells, 2022 - mdpi.com
Integrin β3 plays a key role in the resistance to epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKI), but the development of integrin β3 inhibitors has been stalled …
kinase inhibitors (EGFR-TKI), but the development of integrin β3 inhibitors has been stalled …
Impervious to randomness: confounding and selection biases in randomized clinical trials
P Msaouel - Cancer Investigation, 2021 - Taylor & Francis
The random allocation of therapies in randomized clinical trials is a powerful tool that
removes all confounding biases that can affect treatment assignment. However, confounders …
removes all confounding biases that can affect treatment assignment. However, confounders …